Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
IMMUNOSPEC
Ghent, East Flanders, Belgiumimmunospec.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ImmunoSpec is a specialized biotechnology company focused on immunopeptidomics and the characterization of MHC-associated peptides. The company utilizes advanced mass spectrometry techniques to identify and quantify the repertoire of peptides presented by Human Leukocyte Antigens (HLA) on the surface of cells. This technology is critical for the development of personalized cancer vaccines, T-cell therapies, and the assessment of drug immunogenicity. ImmunoSpec provides high-resolution mapping of the immunopeptidome to support pharmaceutical and biotech partners in target discovery and lead optimization.
- Therapeutic areas
- Infectious DiseasesOncologyImmunology
- Modalities
- ImmunopeptidomicsMass spectrometryProteomics
- Industry
- Drug Discovery Services
Beyond the preview
Go deeper on IMMUNOSPEC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMMUNOSPEC.